NINemat Ibrahi̇mKhanli

Nemat Ibrahi̇mKhanli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nemat Ibrahi̇mKhanli has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endovascular management of vascular complications in hemodialysis patients: a single-center experience

    by Ati̇yE Cenay Karabörk Kiliç, Burak Mert Akhan, Nemat Ibrahi̇mKhanli, Esra Kulaksiz Turan, Fati̇h Öncü, Mehmet Koray Akkan, Ahmet Baran Onal, Erhan Turgut Ilgit

    Background/aim: Vascular access failure remains a major cause of morbidity in patients undergoing hemodialysis. This study aimed to evaluate the types of endovascular interventions performed for hemodialysis-related vascular complications, as well as their technical success and patency outcomes, at a single center. Materials and methods: A total of 103 lesions in 89 patients treated between 2001 and 2023 were retrospectively analyzed. Catheterrelated complications, central venous stenosis or occlusion, and arteriovenous fistula- or graft-related complications were managed using endovascular techniques. Endovascular interventions included catheter repositioning, thrombolysis, percutaneous transluminal angioplasty (PTA), stent placement for central venous lesions, PTA of the fistula vein or feeding artery, and fistula closure. Adjunctive antiplatelet therapy was used selectively, particularly after stent placement. Primary patency rates were assessed at 6 and 12 months in patients with available follow-up data. Descriptive statistics were performed. Results: Of the lesions analyzed, 22% were catheter-related, 51% involved central venous stenosis or occlusion, and 26% were accessrelated. Technical success was achieved in 100% of catheter repositioning cases. The success rate for thrombolysis of occluded catheters was 80%. PTA for central venous lesions had an 86% success rate, while stenting had a 100% success rate. Follow-up data for patency assessment were available in 34 patients. Among patients with available follow-up data, the primary patency rates at 6 and 12 months for central venous lesions treated with PTA were 85% and 70%, respectively. When PTA was combined with stenting in these lesions, primary patency rates at 6 and 12 months were 55% and 33%, respectively. In patients with juxta-anastomotic vein stenosis of an arteriovenous fistula, PTA achieved a 6-month primary patency rate of 60%; however, 12-month follow-up data were unavailable. Fistula closure was technically successful in the single patient who required this procedure. Conclusion: In this single-center retrospective study, endovascular interventions were associated with high immediate technical success in hemodialysis patients with vascular access-related complications. However, patency outcomes should be interpreted cautiously because follow-up data were available only for a subgroup of patients. PTA and selective stent placement may represent useful minimally invasive treatment options for maintaining or restoring vascular access function.

  • Open Access

    Altered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling

    by Kübranur Ünal, Leyla İbRahimkhanlı, Mehmet Emre Erol, Nemat İbRahimkhanlı, Sabri Engin Altıntop, Mahi Nur Cerit, Ethem Turgay Cerit, Halit Nahit Şendur

    Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystem disorder characterized by hepatic lipid accumulation, low-grade inflammation, and metabolic dysregulation. Although the kynurenine pathway has been implicated in the pathogenesis of metabolic and inflammatory diseases, its contribution to MASLD remains unclear. This study aimed to evaluate tryptophan (TRP) metabolism and its relationship with inflammatory biomarkers and lipid parameters across different grades of steatosis. A total of 88 adults (62 MASLD, 26 healthy controls; aged 20-69 years) were enrolled in this study. Serum concentrations of inflammatory markers (CRP, IL-6, and TNF-α) were determined using immunoassay-based methods, and TRP metabolites (TRP, KYN, KYNA, 3-HK, 3-HAA, QA, PIC) were quantified using validated LC–MS/MS. Steatosis grades (0-3) were assessed via ultrasonography. Statistical analyses included the Mann–Whitney U test, the Kruskal–Wallis test, and the Spearman correlation test. MASLD subjects showed significantly higher BMI, triglycerides, AST, ALT, GGT, CRP, TNF-α, and KYNA levels compared with controls (all P < .05), while HDL-C levels were lower ( P = .014). Across steatosis grades, BMI, TG, and CRP increased progressively ( P < .001), and IL-6 showed a positive correlation with steatosis severity ( r = .280, P < .05). KYNA levels were elevated in early steatosis (Grade 1, P = .008) and inversely correlated with TC and LDL-C ( r = −.393 and r = −.384, respectively). The elevation of KYNA may reflect an early compensatory mechanism imitigating hepatic and metabolic stress. Integrating inflammatory and kynurenine pathway biomarkers could improve disease stratification and therapeutic targeting in MASLD.


  • Open Access

    Serum biomarkers and non-invasive indices for discriminating MASLD among adults with dysglycaemia

    by Kübranur Ünal, Leyla İbRahimkhanlı, Mehmet Emre Erol, Sabri Engin Altıntop, Nemat İbRahimkhanlı, Halit Nahit Şendur, Mahi Nur Cerit, Ethem Turgay Cerit

    Objectives: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Although dysglycaemia is a major risk factor, additional cardiometabolic disturbances contribute to the development of MASLD. This study aimed to identify parameters that distinguish MASLD among dysglycaemic individuals using body composition, anthropometric, biochemical, and imaging-based assessments. Methods: In this cross-sectional study, male and female adults were stratified into three groups: dysglycaemic individuals with MASLD (MASLD-Dys), dysglycaemic individuals without MASLD (Dys), and normoglycaemic individuals without MASLD as healthy controls. Imaging-based hepatic fat quantification, body composition, anthropometric and biochemical parameters, and non-invasive indices assessing hepatic steatosis and fibrosis were evaluated. Results: Compared with Dys participants, MASLD-Dys participants had higher body mass index (BMI), waist circumference, trunk fat mass, ultrasound-derived hepatic fat fraction (USFF), and Fatty Liver Index (FLI). The strongest between-group separation was observed for USFF (p<0.001). In receiver operating characteristic analysis, USFF showed the highest discriminative performance for MASLD-Dys vs. Dys, with an area under the curve of 0.925 and an optimal cut-off of ≥6.95 %. Conclusions: USFF was the strongest discriminator of MASLD among dysglycaemic adults, while FLI provided a practical non-imaging alternative. These findings support integrating hepatic fat quantification and body composition measures into MASLD risk stratification beyond glycaemic status alone.